# Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

> **NCT05422066** · PHASE2 · RECRUITING · sponsor: **Li Zhiming** · enrollment: 50 (estimated)

## Conditions studied

- DLBCL Germinal Center B-Cell Type

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05422066
- **Lead sponsor:** Li Zhiming
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-26
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422066, "Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05422066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*